Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CPB1 | P15086 | 1/20 | 0.39 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | EP300 | Q09472 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30337851 | 1.00 | SMN1; SMN2 (0.43) | SMN1; SMN2POLBGRM5EGLN2CPB2 | |
| SCHEMBL31095576 | 0.77 | NOS3 (0.45) | SMN1; SMN2POLBGRM5EGLN2CPB2 | |
| SCHEMBL22199029 | 0.77 | EGLN2 (0.60) | SMN1; SMN2POLBGRM5EGLN2CPB2 | |
| SCHEMBL2159955 | 0.77 | NOS3 (0.45) | SMN1; SMN2POLBGRM5EGLN2CPB2 | |
| SCHEMBL5792550 | 0.76 | NPC1 (0.60) | SMN1; SMN2POLBGRM5EGLN2ALDH1A1 | |
| SCHEMBL16038927 | 0.74 | NPC1 (0.53) | GRM5CPB2HTTCPB1MEN1 | |
| SCHEMBL5100117 | 0.73 | GRM5 (0.47) | SMN1; SMN2POLBGRM5ALDH1A1HTT | |
| SCHEMBL27381147 | 0.73 | GRIN2D (0.38) | CPB2ALDH1A1ARRAB9A | |
| SCHEMBL22185839 | 0.73 | CPB2 (0.44) | SMN1; SMN2POLBGRM5EGLN2CPB2 | |
| SCHEMBL20743016 | 0.73 | PDE10A (0.45) | SMN1; SMN2POLBCPB2PLD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117418280-A | Nickel spraying plating solution, preparation method and electroplating method | 昆山一鼎工业科技有限公司 | 2024-01-19 | — | — | CN | claimed |
| CN-115976586-A | Positive and negative pulse electrolytic nickel-tungsten alloy solution, preparation method, electroplating method and nickel-tungsten alloy coating | 昆山一鼎工业科技有限公司 | 2023-04-18 | — | — | CN | claimed |
| CN-117418280-A | Nickel spraying plating solution, preparation method and electroplating method | 昆山一鼎工业科技有限公司 | 2024-01-19 | — | — | CN | disclosed |
| CN-115976586-A | Positive and negative pulse electrolytic nickel-tungsten alloy solution, preparation method, electroplating method and nickel-tungsten alloy coating | 昆山一鼎工业科技有限公司 | 2023-04-18 | — | — | CN | disclosed |
| US-10640510-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-10640510-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20200079778-A9 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | SUNOVION PHARMACEUTICALS INC. | 2020-03-12 | — | — | US | disclosed |
| US-20190135815-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-05-09 | — | — | US | disclosed |
| US-20190135815-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2019-05-09 | — | — | US | disclosed |
| US-10196399-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-10196399-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2019-02-05 | — | — | US | disclosed |
| EP-2694495-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-02-12 | — | — | EP | disclosed |
| WO-2012170845-A2 | METABOTROPIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF | HEFFERNAN MICHELE L R (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012136603-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-11 | — | — | WO | disclosed |
| US-20120253035-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-10-04 | — | — | US | disclosed |
| EP-1458385-A4 | HETEROARYL SUBSTITUTED IMIDAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040259917-A1 | Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5 | COSFORD NICHOLAS D P (US) | 2004-12-23 | — | — | US | disclosed |
| EP-1458385-A2 | HETEROARYL SUBSTITUTED IMIDAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004030637-A2 | TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE | MERCK & CO., INC. (US) | 2004-04-15 | — | — | WO | disclosed |
| WO-2003053922-A2 | HETEROARYL SUBSTITUTED IMIDAZOLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196399-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | GRM5, GRIK5, GRM2 | SMN1; SMN2 3419/4885POLB 3328/4885GRM5 1/4885 |
| US-20120253035-A1 | 1,4-OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS | BACE2, BACE1, PSEN2 | SMN1; SMN2 966/4885POLB 1832/4885GRM5 814/4885 |
| US-20040259917-A1 | Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRIN2C | SMN1; SMN2 4520/4885POLB 3979/4885GRM5 1/4885 |
| US-20190135815-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | GRM5, GRIK5, GRM2 | SMN1; SMN2 3419/4885POLB 3328/4885GRM5 1/4885 |
| US-20200079778-A9 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | GRM5, GRIK5, GRM2 | SMN1; SMN2 3419/4885POLB 3328/4885GRM5 1/4885 |
| US-10640510-B2 | Metabotrophic glutamate receptor 5 modulators and methods use thereof | GRM5, GRIK5, GRM2 | SMN1; SMN2 3419/4885POLB 3328/4885GRM5 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.